Sign in
Not yet recruitingPhase 3

Efficacy of Prophylactic Levetiracetam for Improving Functional Outcome in the Acute Phase of Intracerebral Haemorrhage: a Randomised, Double-blind, Placebo-controlled, Phase 3 Trial

Key facts

Who runs it
Hospices Civils de Lyon
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 3
People taking part
580 people, planned
Started
2 Oct 2026
Expected to end
2 Oct 2030
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Treatment administration (Levetiracetam or placebo)
  • Neuroimaging
  • National Institute of Health Stroke Scale (NIHSS)
  • Modified Rankin Scale (mRS)
  • Euroqol test (EQ-5D-5L)
  • Montreal Cognitive Assessment (MoCA)
  • Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog)
  • Hospital Anxiety and Depression Scale (HADS)
Record updated
12 August 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Age ≥ 18 years
  • Spontaneous (non-traumatic) supratentorial intracerebral haemorrhage diagnosed by brain CT or MRI
  • Onset of neurologic symptoms within 24 hours
  • NIHSS score on admission ≤ 25
  • Informed consent given by the patient or his/her impartial witness
  • Patients benefiting from a social insurance system or a similar system
  • For women of childbearing age, use of highly effective contraceptive method, which will be continued until the end of relevant systemic exposure of the treatment (i.e 56 hours after end of treatment)

Who cannot take part

  • Patients who have been part of a clinical study involving another investigational product in the previous 30 days or within 5 half-lives of the other investigational product prior to Screening, whichever is longer, or participant is currently receiving an investigational product
  • Previous history of severe depression or psychotic disorder or suicidal attempt
  • Intracerebral haemorrhage known or suspected by study investigator to be secondary to trauma, vascular malformation, haemorrhagic transformation of ischaemic stroke, or tumour
  • Current use of antiseizure drugs or history of epilepsy
  • Patients with inaugural seizures at the onset of symptoms associated with intracerebral hemorrhage
  • Known terminal illness
  • Known allergy or hypersensitivity to levetiracetam or other pyrrolidone derivatives, or any of the excipients
  • Known allergy or hypersensitivity to microcrystalline cellulose or lactose
  • Patients with seizures occurring between the inclusion of the patient and the start of the treatment
  • Patients with QTc prolongation
  • Severe renal insufficiency (creatinine clearance < 30 ml/min)
  • Positive pregnancy test at inclusion for women of childbearing age
  • Pregnancy or breastfeeding
  • Patients taking probenecid, methotrexate or macrogol
  • Being under legal protection

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Epileptic seizures are a common complication at the acute phase of intracerebral haemorrhage (ICH). The incidence of seizures occurring within 7 days reaches 40% when subclinical seizures are diagnosed by continuous electroencephalogram (EEG).

Read full original descriptionShow less

Some studies have suggested that early seizures are associated with haematoma expansion (Vespa., Neurology 2003), worse neurological outcomes (Gilmore., Stroke 2016) or increased mortality. By contrast, other studies have shown no association of acute seizures with long-term mortality and outcome. However, the interpretation of these works is subject to bias because almost all studies were based on clinical detection of seizures only, while it has been shown that most early seizures after ICH are clinically unrecognised and can only be diagnosed with EEG monitoring.

The PEACH trial, a double-blind, randomised, placebo-controlled, showed that clinical and/or electrographic seizures occur in more than 40% of patients with ICH and that Levetiracetam (LVT) is safe and effective in preventing these seizures. However, it remains unclear whether preventing acute seizures might lead to improved functional outcomes after ICH. An adequately powered randomised controlled trial is needed to answer whether primary seizure prophylaxis improves functional outcome in this setting. Answering this question would result in an important change in ICH acute care guidelines, which currently do not recommend primary prophylactic antiseizure treatment. As compared to research in acute ischemic stroke management, fewer clinical trials have been conducted in acute ICH and no effective medical treatments are available in this subset of patients.

The main objective of PEACH 2 is to establish if prophylactic antiseizure therapy with LVT improves functional outcome in adults with acute spontaneous ICH. Functional outcome assessed by the modified Rankin score (mRS score) six months after acute ICH will be compared between patients receiving prophylactic antiseizure therapy with levetiracetam and patients receiving placebo.

The secondary objectives are to examine the effect of prophylactic antiseizure therapy with levetiracetam versus placebo on:

* the number of early and late clinical seizures, on the short term and long term evolution of the neurologic deficit as assessed by the NIHSS, on long term functional outcome (12 months) as assessed by the mRS, on quality of life and cognitive impairment, and on haematoma expansion and mass effect on control brain imaging * the frequency of side effects at 1 and 6 months, pneumonia at 1 month, delirium at 1 month, irritability/aggressivity, anxiety and depression at 1 and 6 months, and all-cause mortality at 1, 6 and 12 months.

580 patients will be recruited over 3 years.

The 2 groups in the trial

  • Intervention GroupExisting treatment, for comparison

    290 patients will be recruited over 3 years in the intervention group. In this group, Levetiracetam should be initiated within 24 hours of randomisation. Levetiracetam (500 mg every 12 hours) will be administered intravenously for at least 48 hours and then the route of administration will be changed to oral administration at the same dosage after assessment of swallowing function. The treatment period will be 30 days at full dose, followed by a gradual tapering over 2 weeks (250 mg of levetiracetam every 12 hours for 7 days, followed by 250 mg of levetiracetam every 24 h for 7 days).

    Treatment: Treatment administration (Levetiracetam or placebo), Neuroimaging, National Institute of Health Stroke Scale (NIHSS), Modified Rankin Scale (mRS), Euroqol test (EQ-5D-5L), Montreal Cognitive Assessment (MoCA), Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog), and Hospital Anxiety and Depression Scale (HADS)

  • Control GroupPlacebo, for comparison

    290 patients will be recruited over 3 years in the control group. In this group, the placebo (microcrystalline cellulose) should be initiated within 24 hours of randomisation. The placebo (500 mg every 12 hours) will be administered intravenously for at least 48 hours and then the route of administration will be changed to oral administration at the same dosage after assessment of swallowing function. The treatment period will be 30 days at full dose, followed by a gradual tapering over 2 weeks (250 mg of placebo every 12 hours for 7 days, followed by 250 mg of placebo every 24 h for 7 days).

    Treatment: Treatment administration (Levetiracetam or placebo), Neuroimaging, National Institute of Health Stroke Scale (NIHSS), Modified Rankin Scale (mRS), Euroqol test (EQ-5D-5L), Montreal Cognitive Assessment (MoCA), Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog), and Hospital Anxiety and Depression Scale (HADS)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
12 August 2026